Aclacinomycin A

Aclacinomycin A (Aclarubicin) is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A is an inhibitor of topoisomerase I and II. Aclacinomycin A inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis[1][2][3].

Product Specifications

CAS Number

[57576-44-0]

Product Name Alternative

Aclarubicin

UNSPSC

12171500

Hazard Statement

H301

Target

Antibiotic; DNA/RNA Synthesis; Proteasome; Topoisomerase

Type

Dye Reagents

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/aclacinomycin-a.html

Purity

99.03

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C([C@@H]1C2=CC(C(C3=CC=CC(O)=C43)=O)=C(C4=O)C(O)=C2[C@@H](O[C@@](O[C@@H](C)[C@H]5O[C@@](O[C@@H](C)[C@H]6O[C@](CCC7=O)([H])O[C@H]7C)([H])C[C@@H]6O)([H])C[C@@H]5N(C)C)C[C@]1(O)CC)OC

Molecular Formula

C42H53NO15

Molecular Weight

811.87

Precautions

H301

References & Citations

[1]Isoe T, et al. Inhibition of different steps of the ubiquitin system by CDDP and aclarubicin. Biochim Biophys Acta. 1992 Sep 15;1117 (2) :131-5.|[2]Hajji N, et al. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005 May 2;583 (1) :26-35.|[3]Iihoshi H, et al. Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells. Toxicol Lett. 2017 Aug 5;277:109-114. |[4]Hori S, Shirai M, Hirano S, Oki T, Inui T, Tsukagoshi S, Ishizuka M, Takeuchi T, Umezawa H. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gan. 1977 Oct;68 (5) :685-90.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light)

Scientific Category

Dye Reagents

Clinical Information

Launched

Isoform

Topo I; Topo II

Citation 01

Biomolecules. 2025 Jul 6.|Patent. US20250129329A1.|Bioengineered. 2022 Feb;13 (2) :2207-2216.|bioRxiv. 2023 Jan 13.|Int J Hyperthermia. 2022;39 (1) :998-1009.